Menstrual Migraine
Menstrual migraine affects up to 60% of women with migraine. Attacks occurring around menstruation are typically longer, more severe, and more resistant to acute treatment than non-menstrual attacks. The ICHD-3 distinguishes pure menstrual migraine (exclusively perimenstrual) from menstrually related migraine (perimenstrual plus other times). Management combines acute optimization with short-term perimenstrual prophylaxis or continuous hormonal strategies.
Bottom Line
- Definition: Attacks occurring within day −2 to +3 of menstruation onset, documented over at least 2 of 3 consecutive cycles
- Pure menstrual migraine (~10%): Attacks exclusively perimenstrual. Menstrually related migraine (~50%): Perimenstrual plus additional attacks at other times
- Mechanism: Estrogen withdrawal in the late luteal phase triggers trigeminal activation and increases CGRP sensitivity
- Acute treatment: Triptans work but often need longer-acting agents (frovatriptan, naratriptan) or repeated dosing due to longer attack duration
- Short-term prophylaxis: Frovatriptan 2.5 mg BID starting day −2 through day +3 is the best-studied perimenstrual mini-prevention
- Hormonal strategies: Continuous combined OCP (skip placebo), estradiol patch perimenstrually, or continuous progestin-only methods
ICHD-3 Criteria
| Type | Criteria | Prevalence |
|---|---|---|
| Pure menstrual migraine without aura (A1.1.1) | Attacks exclusively on day −2 to +3 of menstruation in ≥2 of 3 consecutive cycles, with no attacks at other times | ~10% of women with migraine |
| Menstrually related migraine without aura (A1.1.2) | Attacks on day −2 to +3 of menstruation in ≥2 of 3 consecutive cycles, with additional attacks at other times | ~50% of women with migraine |
| Non-menstrual migraine | No consistent perimenstrual pattern | ~40% of women with migraine |
Diary documentation is essential. Patients often overestimate the menstrual association. A 3-month headache diary correlated with menstrual dates is needed to confirm the diagnosis.
Pathophysiology
- Estrogen withdrawal hypothesis: The late-luteal decline in estradiol (not absolute levels) triggers migraine. A drop of >10 μg/L over 5-6 days is the threshold in experimental models.
- Estrogen modulates: Serotonin synthesis and receptor expression, CGRP release threshold, prostaglandin production, and endogenous opioid tone
- Prostaglandins: Endometrial prostaglandin release peaks at menstruation and may contribute to both dysmenorrhea and migraine via systemic sensitization
- Why menstrual attacks are worse: Longer duration (often 48-72 hours vs 12-24), higher pain intensity, greater triptan resistance, and higher recurrence rate within 24 hours of initial treatment
Acute Treatment
Optimizing Acute Treatment for Menstrual Attacks
- Long-acting triptans preferred: Frovatriptan (25-hour half-life) or naratriptan (6-hour half-life) have lower recurrence rates than sumatriptan for menstrual attacks
- Frovatriptan 2.5 mg: Best evidence for menstrual migraine — lower 24-hour recurrence (~17%) than sumatriptan (~30%) in head-to-head trials
- NSAID loading: Naproxen 500 mg with a triptan is effective for prolonged attacks; naproxen also addresses prostaglandin-mediated component
- Combination approach: Triptan + NSAID at onset, with planned repeat dosing over the vulnerable window
- Rescue: If 48-72 hours of refractory attack, consider dexamethasone 4-8 mg single dose or GON block
Short-Term (Perimenstrual) Prophylaxis
For women with predictable cycles and confirmed menstrual pattern, short-term prophylaxis around the vulnerable window (day −2 to +3) can prevent attacks without continuous medication.
| Agent | Regimen | Evidence | Notes |
|---|---|---|---|
| Frovatriptan | 2.5 mg BID, day −2 to +3 | Level A (best evidence). 3 RCTs; reduced menstrual migraine incidence by ~50% | Preferred first-line mini-prophylaxis. Well-tolerated. |
| Naratriptan | 1-2.5 mg BID, day −2 to +3 | Level B. Newman et al. (2001): reduced menstrual attacks vs placebo | Alternative to frovatriptan; similar approach |
| Zolmitriptan | 2.5 mg BID or TID, day −2 to +3 | Level B. Tuchman et al. (2008): positive RCT | Shorter half-life; may need TID dosing |
| Naproxen | 500 mg BID, day −2 to +7 | Level B. Addresses prostaglandin component | Can combine with triptan; also treats dysmenorrhea |
| Magnesium | 360 mg/day starting day 15 of cycle through menstruation | Limited evidence. Facchinetti et al. (1991): positive small RCT | Low risk; may use as adjunct |
Triptan Mini-Prophylaxis Limitations
- Requires predictable cycle timing — less useful with irregular menses
- Risk of medication overuse headache is low with 5-6 days/month but should be monitored if attacks also require triptan treatment at other times
- Not suitable for patients with migraine with aura + vascular risk factors who should avoid triptans
Hormonal Strategies
Estrogen Supplementation
- Perimenstrual estradiol patch: 100 μg/24h patch applied on day −2 through day +5 to prevent the estrogen drop
- MacGregor et al. (2006): Estradiol patch reduced menstrual migraine days vs placebo; attacks may rebound when patch is removed
- Estradiol gel 1.5 mg/day perimenstrually is an alternative
- Key issue: rebound migraine can occur when supplemental estrogen is withdrawn — tapering or extending the patch window may help
Continuous Hormonal Contraception
| Strategy | Approach | Notes |
|---|---|---|
| Extended-cycle OCP | Skip placebo week; take active pills continuously for 3-6 months | Eliminates estrogen withdrawal. Only for migraine without aura (combined OCP contraindicated with aura). |
| Desogestrel (progestin-only pill) | Continuous daily dosing | Safe in migraine with aura; suppresses ovulation and stabilizes hormones. Evidence from small trials. |
| LNG-IUS (Mirena) | Levonorgestrel intrauterine system | Reduces menstrual migraine in some patients by thinning endometrium and reducing prostaglandin production. Does not reliably suppress ovulation. |
| GnRH agonists | Leuprolide + add-back estrogen/progesterone | Last resort. Creates medical menopause. Effective but impractical for long-term use (bone loss). Research tool. |
Combined OCP and Migraine with Aura
- Combined estrogen-containing contraceptives are contraindicated in migraine with aura due to increased ischemic stroke risk (ACOG, WHO MEC Category 4)
- Progestin-only methods are safe in migraine with aura
- If a patient on combined OCP develops new aura, discontinue the combined OCP
Standard Preventive Therapy
- Women with menstrually related migraine who also have frequent non-menstrual attacks should be on continuous daily preventive therapy (not just perimenstrual prophylaxis)
- All standard preventives (beta-blockers, antiepileptics, CGRP mAbs, etc.) reduce menstrual and non-menstrual attacks alike
- CGRP mAbs have been shown to reduce menstrual migraine days in subgroup analyses of STRIVE, HALO, and PROMISE trials
- Combine continuous prevention with short-term perimenstrual prophylaxis if menstrual attacks persist despite daily treatment
References
- MacGregor EA. Menstrual and perimenopausal migraine: a narrative review. Maturitas. 2020;142:24-30.
- Silberstein SD, et al. Frovatriptan for the prevention of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Neurology. 2004;63(2):261-266.
- Newman L, et al. Naratriptan as short-term prophylaxis of menstrually associated migraine: a randomized, double-blind, placebo-controlled study. Headache. 2001;41(3):248-256.
- MacGregor EA, et al. Randomized, double-blind, placebo-controlled study of transdermal estrogen replacement therapy for menstrual migraine. Cephalalgia. 2006;26(6):667-673.
- Vetvik KG, MacGregor EA. Menstrual migraine: a distinct disorder needing greater recognition. Lancet Neurol. 2021;20(4):304-315.